Group 1 - The SPDR S&P Biotech ETF (NYSEARCA:XBI) is identified as a trending stock this week, with a positive outlook for a breakout in the coming months [1] - Joseph Terranova, a Senior Managing Director at Virtus Investment Partners, plans to purchase the XBI ETF, indicating a target price of around 92, while the current price is 103, suggesting a cautious investment strategy [1] - Terranova believes that the XBI is in the midst of a multi-year breakout, projecting significant growth over the next six to nine months [1] Group 2 - There is a belief that certain AI stocks may offer higher returns with limited downside risk compared to the XBI ETF, indicating a competitive investment landscape [2] - A report is available that highlights an extremely cheap AI stock that benefits from Trump tariffs and onshoring, suggesting alternative investment opportunities [2]